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Although partly disease-irrelevant, intrathecal immunoglobulins (Ig) synthesis is a typical
feature of multiple sclerosis (MS) and is driven by the tertiary lymphoid organs (TLO).
A long-known hallmark of this non-specific intrathecal synthesis is the MRZ pattern, an
intrathecal synthesis of Ig against measles, rubella, and zoster viruses. This non-specific
intrathecal synthesis could also be directed against a wide range of pathogens. However,
it is highly problematic since brain TLO should not be able to drive the clonal expansion
of lymphocytes against alien antigens that are thought to be absent in MS brain. We pro-
pose to explain the paradox of non-specific intrathecal synthesis by discussing the natural
properties of TLO. In fact, besides local antigen-driven clonal expansion, circulating plas-
mablasts and plasma cells (PC) are non-specifically recruited from blood and gain access
to survival niches in the inflammatory CNS. This mechanism, which has been described
in other inflammatory disorders, takes place in the TLO. As a consequence, PCs recruited
in brain mirror the individual’s history of immunization and intrathecal synthesis of IgG in
MS may target a broad range of common infectious agents, a hypothesis in line with epi-
demiological data. Moreover, the immunization schedule and its timing may interfere with
PC recruitment. If this hypothesis is correct, the reaction against EBV appears paradoxical:
although early infection of MS patients is systematic, intrathecal synthesis is far lower than
expected, suggesting a crucial interaction between MS onset and timing of EBV infection.
A growing body of evidence suggests that the non-specific intrathecal synthesis observed
in MS is also common in many chronic CNS inflammatory disorders. Assuming that corti-
cal TLO in MS are associated with typical sub-pial lesions, we have coined the concept of
“TLO-pathy” to describe these lesions and take examples of them from non-MS disorders.
Lastly, we propose that intrathecal synthesis could be considered a strong hallmark of CNS
TLO and might be used to monitor future TLO-targeted therapies.
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INTRODUCTION
The intrathecal synthesis of immunoglobulins (Ig) and oligoclonal
bands (OCB) is an early occurring event in the course of multiple
sclerosis (MS), and once acquired, persists essentially unchanged
throughout life, whatever therapies are undertaken [see review in
Ref. (1)]. As a consequence, intrathecal Ig secretion is still a major
supportive diagnostic argument. However, the antigens targeted by
these intrathecal Ig are often considered to be largely unknown and
studies have yielded contradictory results (2). The lack of speci-
ficity against the three major myelin proteins does not preclude any
other specificity (3), either against other minor myelin proteins or
brain antigens,or against foreign antigens (viral antigens for exam-
ple). Indeed, the failure to find a major antigen for an intrathecally
synthesized Ig may not relate to a nonsense antibody production
but instead may reflect the molecular complexity of the CNS and
the presumed antigenic target. Studies without any a priori, which
are better suited to revealing unknown specificities, have con-
firmed the existence of an immense pool of targets against other
brain membrane proteins, lipids, and glycolipids [see Ref. (3)].
Paradoxically and despite these huge efforts, the puzzling problem
of non-brain targets directed against a virus in the absence of brain
infection seems irreconcilably contradictory with an intrathecal
antigen–antibody selection. Although the concept of molecular
mimicry has long been debated [review in Ref. (4)], epidemiologi-
cal data suggest that mimicry alone cannot explain the intrathecal
synthesis that occurs against so many infectious agents [(5, 6), see
below]. Here, we reassess the pathophysiological consequences of
this non-specific (disease-irrelevant) intrathecal reaction in MS in
the light of the most recent immunological data and develop a new
concept with great explanatory potential by bringing together the
apparently contradictory data in the literature.
First, we comprehensively review the non-specific intrathecal
reaction in MS. While the classical “MRZ pattern” is the hallmark
of this non-specific reaction, we argue that MRZ is simply part of
a broader non-specific reaction involving many non-brain targets,
such as most of the common infectious agents.
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We then explore the conditions necessary to produce and
maintain an intrathecal reaction. We first use the example of
peripheral (non-brain) lymphoid organ physiology to demon-
strate how a sustained antibody secretion may take place in a
given lymphoid organ, even if the mature B-cells originate from a
different immune compartment. We posit that disease-irrelevant
Ig secretion is a common feature of tertiary lymphoid organs
(TLO) in various inflammatory disorders. We then link these
observations to the fact that intrathecal synthesis needs the pres-
ence of cortical TLO, implying in turn a non-specific intrathecal
synthesis.
We then explain why virtually all the CNS disorders associ-
ated with intrathecal synthesis may also harbor some non-specific
synthesis, and provide evidence for this reaction and its extent in
multiple CNS inflammatory disorders. Since intrathecal synthesis
involves CNS TLO and bearing in mind that TLO in progres-
sive MS are associated with sub-pial lesions (7), we propose the
pathological concept of “TLO-pathy” and provide examples from
chronic CNS infections.
Finally, we return to the issue of MS. Since non-specific
intrathecal synthesis is directed against many infectious agents, the
question arises as to whether an immunization schedule could be
used to accurately assess the time of MS onset? Secondly, although
EBV infection precedes MS in virtually all patients, the intrathe-
cal reaction against EBV is paradoxically very low. This might
either illustrate the role of the immunization schedule or a specific
relationship between EBV and MS.
In practice, intrathecal synthesis in MS informs the clini-
cian mostly of the persistence of CNS TLO at the pathological
level. Such information obtained from a simple lumbar punc-
ture could help in the monitoring of future treatments targeting
CNS TLO.
THE CONCEPT OF NON-SPECIFIC INTRATHECAL SYNTHESIS
IN MS
THE “MRZ” PATTERN – A TYPICAL NON-SPECIFIC INTRATHECAL
RESPONSE
Barring a still unknown cross-reactivity from viral particles and
the brain, the “MRZ” reaction, which is the intrathecal synthesis
of Ig against measles, rubella, and varicella-zoster virus, has long
been considered to be highly specific of MS, but does not target the
brain (8). The IgG fraction that belongs to this specific response
in the CSF is estimated to represent <2% of the total amount of
CSF IgG (8–10) and only a minor fraction of total OCB (11–13),
but it is one that has a major diagnostic specificity. Moreover, the
MRZ reaction is observed in MS patients although none have been
reported to have intrathecal production of these viruses or to suffer
from encephalitis involving any of these viruses. The proportion
of MS patients having an elevated antibody index (AI) against≥1
of these viruses is 89% (8), and increases over time and MS evo-
lution. About one-third of patients also react against Herpes virus
(MRZH). The MRZ reaction, which is sometimes present in the
absence of OCB, is more frequent in clinically isolated syndromes
(CIS) who will soon convert (14) and its proportion increases in
OCB-negative patients during follow-up (15). In a retrospective
study of MRZH in OCB-negative patients, 4 (18%) of 22 patients
having been diagnosed with MS within the last 5 years had at least
one elevated AI, compared to 17/28 (61%) in those with a longer
disease duration (15).
Intrathecal synthesis is poly specific in about a quarter of MS
patients: one elevated AI (against M, R, Z, or H) in 22%, two AI
in 17%, three AI in 4%, and four AI in 2% (15). The number of
elevated AI strongly correlated both with age at spinal tap and
disease duration (15). Immunosuppressive treatments (mitox-
antrone and azathioprine) seem ineffective to prevent persistence
of the MRZ pattern (16). Titers of AI against MRZ correlated
with the T2 load in MRI, significantly for measles AI and with
a trend for rubella and zoster AI (17). However, this correlation
is limited to the early phase of the disease since intrathecal Ig
secretion is rather stable over time, although white matter T2 load
increases (17), but no data is available to correlate with gray mat-
ter lesions. Unlike in controls, no decline in AI levels occurs with
age in MS patients either considering serum or CSF titers, and
there is even a slight increase (18, 19). Moreover, there is a trend
to a higher proportion of elevated AI in SP-MS than in RR-MS
patients (20).
BROADENING THE MRZ PATTERN TO MULTIPLE INFECTIONS
Beyond the MRZ pattern, high intrathecal synthesis against many
other infectious agents has been reported in MS: rotavirus (21);
toxoplasmosis in 10% (8, 10); herpes in one-third of cases (8,
21); Chlamydia pneumonia in 20–82% (9, 11, 20, 22–25); HHV6
in 20–30% (26, 27); Borrelia burgdorferi in 26% (28); mumps
(29); influenza B (29); rotavirus (29); adenovirus (30); and vac-
cinia (30, 31). In each study, seroprevalence for infection was the
same in both MS and controls, whereas controls had no specific
intrathecal reaction. Unfortunately, some of these older studies
used heterogeneous methodologies and some of them should be
validated with recent stringent criteria (10). The same gradient
of frequency from RR-MS to SP-MS is observed with intrathe-
cal productions against many infectious agents (20, 22). This
polyspecific intrathecal IgG response in MS mirrors the indi-
vidual’s history of previous infections and immunization and
depends on the local prevalence of each disorder. For exam-
ple, a lower proportion of rubella-AI is observed in MS patients
from Cuba than those from Germany, in line with a lower inci-
dence of rubella infection (6). Interestingly, the sex-ratio is far
lower (M:F= 1:6) than expected (M:F= 1:1.9) in Cuban patients
synthesizing intrathecal rubella antibodies, a finding reliably
explained by immunization campaigns directed toward females
(but not males) in a context where natural infection is very
low (6). In Czech patients, a high proportion of AI against B.
burgdorferi has been observed (up to 26%) (28). In fact, the
rate of intrathecal reaction against a given germ correlates with
the rate of seroprevalence, very highly seroprevalent infections
(about 90% for measles and rubella) having the higher rate of
intrathecal reactivity whereas low prevalence of HSV is associated
with scarce reaction (29). This former epidemiological subjec-
tion and the broad range of infectious agents potentially involved
plead against a trivial cross-reactivity of intrathecal synthesis with
brain antigens. We hypothesize that a high level of intrathecal
reaction against all the common antigens (infectious/vaccinal or
not) is probably common in MS and could throw light on the
pathophysiology of MS.
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KEY PROPERTIES OF CNS TERTIARY LYMPHOID ORGANS
EXPLAIN INTRATHECAL SYNTHESIS, INCLUDING
NON-SPECIFIC SECRETION
PLASMA CELLS MAY LOCATE NOT ONLY IN BONE MARROW BUT ALSO
WIDELY THROUGHOUT THE PERIPHERAL LYMPHOID ORGANS
The protracted presence of intrathecally secreted IgG against infec-
tious agents sparing brain supposes the non-specific recruitment
and survival in the intrathecal compartment of long-lived plasmo-
cytes originating from a different immune compartment, where
the B-cell response against infectious agents previously took place.
The ability to develop an immune response in a compartment and
to transfer specific B-cells to another unexposed compartment is
a common immunological feature outside of the brain (32, 33).
During immune activation in the periphery, naïve B-
lymphocytes encountering antigens are committed to plasmablasts
and undergo hypermutation in germinal centers of secondary lym-
phoid organs. Then, specific plasmablasts appear in the blood for
a few days on their way to the survival niches, where they differ-
entiate into plasma cells (PC) (32) (Figure 1). Most of the niches
are situated in bone marrow (a primary lymphoid organ) (34).
Since the frequency of PC in bone marrow is constant through-
out life (about 0.5%), newly formed plasmablasts migrating to
bone marrow compete with PC already occupying survival niches
(34). Thus a majority of newly formed plasmablasts arriving in
the bone marrow fail to locate to an appropriate niche (32). This
competition for a limited number of survival niches may play a key
role in the regulation of serum antibody levels and has also been
demonstrated in different animal species (34). However, niches
are also available in peripheral secondary and TLO where they
display the ability to retain the newly formed PC (32, 35–39). The
retention frequency of PC for a given specificity strongly depends
on the lymphoid organ: for example, PC against tetanus toxin
preferentially reside in secondary lymphoid organs such as ton-
sils, and their antibody titers stem from this compartment (35).
It also depends on the route of immunization, making specific
B-cells more numerous in the draining lymph nodes although
they are present to a lesser extent throughout the lymphoid sys-
tem: for example, a massive rectal immune response is obtained
after rectal immunization, yet a rectal response, although minor,
is also obtained after gastric or systemic immunization (33). The
frequency of disease-irrelevant PC in TLO does not depend on
the underlying disorder: for example, the same anti-tetanus toxin
IgG concentration is obtained in the culture of synovial extracts
(containing TLO) from osteoarthritis or rheumatoid arthritis (38)
as in chronic graft rejection (37). It thus appears that non-specific
Ig secretion is a natural condition of peripheral TLO.
ARE ANTIBODY-SECRETING CELLS HOSTED IN TLO SURVIVAL NICHES,
THUS EXPLAINING THE MRZ PATTERN BY NON-SPECIFIC NICHES
OFFERED BY CNS INFLAMMATORY LESIONS?
Depending on the primary antigenic stimulation, the estimated
half-life of long-lived PC varies from 11 years (tetanus) to more
than 100 years (measles, mumps), but long-lived PC expelled from
niches during competitive process undergo apoptosis (39). In fact,
prolonged survival necessitates an anti-apoptotic environment
provided in the survival niches by multiple factors (multicom-
ponent PC niche) [review in Ref. (32, 39)]. Although the complex
factors conditioning recruitment, differentiation and survival of
PC in niches are still incompletely deciphered and vary depending
on the different immune compartments (32), CXCL12 expression
by stromal cells and vasculature is the major determinant to retain
blood plasmablasts in bone marrow (32, 34). In MS, CXCL12 is
elevated in CSF, secreted by astrocytes (40), and expressed in the
endothelial lumen of lesions in the vicinity of lymphoid infiltrates
(41) where PC infiltrates are usual, suggesting that MS brain is
ideally equipped to retain non-specific circulating plasmablasts.
Although no data is available for meningeal lesions, one could also
expect a meningeal CXCL12 expression similar to that in deep
lesions (41). The presence of PC inside white matter lesions and
meninges in MS has already been described (42, 43). According to
the previous hypothesis, peripherally activated plasmablasts spe-
cific to infectious agents may egress from blood owing to CSF
attractant chemokines secreted in brain lesions (i.e., CXCL12),
reach survival niches in the CSF and brain,differentiate to PC with-
out any antigen (re)challenging, and finally secrete non-specific
intrathecal IgG over a long period (Figure 2). Another mode of
interaction of PC in survival niches may involve T-cells, since PC
depletion in lymphoid organs following alemtuzumab treatment
may be associated with the loss of other cells supporting PC sur-
vival (36). Although these data were obtained in experimental
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FIGURE 1 | Schematic Ig synthesis pathway. Naïve B-cells are classically
recruited in lymphoid organs where they undergo somatic hypermutation,
proliferate, and recirculate as short-lived plasmablasts (PB). PB migrate to
bone marrow, differentiate to long-lived plasma cells (PC), and synthesize the
bulk of plasmatic IgG. However, secondary/tertiary lymphoid organs may also
retain PC in survival niches, where they participate in IgG synthesis.
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FIGURE 2 | Role of tertiary lymphoid organs in intrathecal
synthesis. CNS TLO are able to mount a classical antigen-driven T and
B-cell clonal response that is responsible for intrathecal synthesis
against brain-borne (and possibly disease-relevant) antigens (1, 46–48)
(upper part of figure). A hypothetical pathway (lower part of figure) may
involve the non-specific recruitment of circulating plasmablasts (PB) and
plasma cells (PC) from blood by CNS TLO. These disease-irrelevant PB
may further differentiate after proliferation to PC, home in on survival
niches provided by TLO and maintain the non-specific intrathecal Ig
synthesis.
settings unrelated to MS, they offer an attractive explanation of
the (slight) repression of intrathecal synthesis observed for the
first time in MS patients treated with natalizumab (44, 45).
Similar to MS, the extreme versatility of disease-relevant anti-
bodies and the presence of disease-irrelevant antibodies like anti-
tetanus toxin have been directly associated with TLO function
[chronic graft rejection (37), rheumatoid arthritis (38)]. We sug-
gest that the intrathecal production of disease-irrelevant antibod-
ies may be due to antibody-secreting cells harvested in survival
niches of TLO, as in numerous other peripheral disorders (37,
38). Definitive proof – but hard to obtain – would be obtained
by using in vitro cultures of explanted MS TLO and assaying
disease-irrelevant antibodies in the supernatant. Moreover, since
most experiments to date concerning Ig secretion in body com-
partments have been done with anti-tetanus toxin, it would be
interesting to evaluate AI anti-tetanus toxin in MS patients, in
whom high levels could be expected to occur frequently.
Under these assumptions, a protracted polyspecific Ig response
would indicate an enhanced pre-existing B-cell promoting envi-
ronment. The MRZH pattern mainly mirrors the commonest
infections, i.e., those that are the most likely to select abun-
dant specific plasmocytes, which are subsequently recruited non-
specifically by the brain TLO. Moreover, intrathecal antibody-
secreting cells recruitment should be progressive and achievement
of a full MRZ pattern may take years or even decades. This is
in fact observed in clinical studies where mean age at spinal tap
and disease duration correlate with the number of elevated anti-
body indices (15). Half of the patients having fewer than 5 years of
disease duration have no elevated AI (MRZ), whereas 70% of those
with more than 10 years duration have AI ≥2 (15). It would be of
particular theoretical interest to confirm the MRZ pattern in MS
patient populations where OCB prevalence is lower, in association
with HLA DRB1*04 (15).
The presence of a polyspecific intrathecal synthesis as soon as
the index event occurs suggests that an enhanced B-cell-promoting
environment exists before or at the time of the first event, and
gives a high probability of a chronic inflammatory process already
underway at the moment of the first clinical symptom (6). This
raises two further issues: (1) a polyspecific intrathecal response
might also be associated in non-MS patients susceptible to CNS
TLO (e.g., in chronic CNS infections); (2) the schedule of periph-
eral non-specific infections (e.g., MRZH infections) might inter-
fere with the ancientness of the TLO-leading disease (i.e., MS or
brain infection) in the risk of developing a bystander non-specific
intrathecal synthesis.
NON-SPECIFIC SYNTHESIS IS ALSO A FEATURE OF NON-MS
CNS DISORDERS HARBORING INTRATHECAL SYNTHESIS
NON-SPECIFIC VS. INFECTION-RELATED INTRATHECAL ANTIBODY
SYNTHESIS
The fraction of a specific antibody response against an infectious
agent within the complete intrathecal IgG response is called the
Specific Fraction (F s) (49). For example, the calculation of an
F s value for measles at 2% means that 2% of the total intrathe-
cal IgG response is directed against measles. Neuro-infections are
expected to be associated with very high F s against the virus: F s are
8.8% (3.5–12.5%) for HSV in HSV encephalitis (HSVE), 18.8%
(11.8–27.5%) for measles in subacute sclerosis panencephalitis
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FIGURE 3 | Fraction of intrathecal Ig secretion in various disorders.
Disease-related Ig secretion is minor even in infectious disorders (See Ref.
in text). Intrathecal synthesis is mostly dominated by non-specific
synthesis, including an MRZH pattern, which represents a minor proportion.
Disease-related secretion in MS and MRZH patterns in infections are as yet
unknown.
(SSPE) (49, 50) and 45% (13–73%) for VZV encephalitis (51).
Unfortunately F s values for relevant infectious agents are not
available in other infectious settings such as neuro-syphilis and
neuro-borreliosis. In EBV-associated post-transplantation brain
lymphoma, median F s anti-EBV is 27.8% (14–53.6%) (52).
In MS, each specificity in the MRZH reaction typically retains
a very low median F s of 0.2–1.3% (ranging from 0.03 to 5.3)
(49, 51, 52) and comparable results are obtained for F s anti-EBV
(52). These specific F s results in neuro-infections are about 40-fold
higher than those found in MS patients without overlap. Interest-
ingly, in two cases of HSVE, median F s anti-VZV were 0.3–4.9%, in
the same range as those of MS patients (51). In other words, about
80% of the intrathecal Ig in infectious pathologies are directed
against non-causative antigens (10, 49, 50), i.e., a non-specific
intrathecal synthesis is very common even in neuro-infections
(Figure 3).
The specific antibody fraction of the total IgG in blood (Rs) cor-
responds to the intrathecal fraction of antibodies in CSF (F s) (49).
For example an Rs value for IgG against measles of 0.1% means
that a 0.1% of the total IgG pool is directed against measles. Median
Rs values range from 0.06 to 0.19% (0.01–1.4%), which is a very
low fraction of total blood IgG and does not differ between MS
patients and controls (8). The median ratio F s:Rs for MRZ is 3–3.5
with a wide range extending from 0 to 47.4 (10, 49), confirming a
more intense intrathecal synthesis of specific antibodies.
The variability in the amount of specific intrathecal synthesis
between neurological infections and MS patients as compared to
blood deserves discussion. The amount of intrathecally secreted
specific antibodies should be proportional to the number of
intrathecal PC. If we consider that circulating PC are non-
specifically and randomly selected from blood to home to CNS
TLO, the relative proportion of each specific IgG synthesis in CSF
should grossly parallel their proportion in blood. For example,
if IgG secretion in blood against viruses V1 and V2 is 0.5 and
1% of the total blood IgG, one could expect the same propor-
tion and the same ranking of IgG secretion against those viruses
in CSF. Yet this is not the case. The ranking of specific anti-
bodies concentrations in blood and CSF differs in 67% of MS
patients, confirming that CSF IgG secretion does not simply mir-
ror blood secretion. Intrathecal synthesis of the specific antibodies
occurs independently from each other (49). We propose two non-
mutually exclusive explanations. A first hypothesis involves the
differential intrathecal proliferation of specific B-cells after being
recruited from blood but before being committed to terminal dif-
ferentiation into PC, owing to a favorable intrathecal lymphoid
environment. Unfortunately, no data is available about the clonal-
ity of the IgG involved in the MRZ response. A second hypothesis
posits a non-random brain homing of circulating plasmablasts. It
seems unlikely that plasmablast homing is driven by IgG speci-
ficity. Rather, the critical intensity of plasmablast/PC recruitment
to brain owing to the intensity of the peripheral immune response
to infection could be involved. For example, since immunity is now
largely obtained by vaccination, which has been used for almost
30 years, rather than by infection; has intrathecal synthesis against
measles changed over time? A study suggests that patients with
a history of measles infection are more prone to have detectable
anti-measles antibodies in the CSF (89 vs. 67%) and at higher
levels than those who have been vaccinated (19). Unfortunately,
rates of CSF anti-measles secretion were not correlated to age at
infection and an exact determination of intrathecal synthesis was
lacking, so further studies on this theme are required.
POLYSPECIFIC INTRATHECAL SYNTHESIS IN NON-MS DISORDERS
The polyspecificity of the intrathecal response is not restricted to
MS but is also common in response to infections [see above (49)]
or non-MS CNS inflammation.
(a) Autoimmune disorders. In large control groups of non-
autoimmune and autoimmune non-MS neurological disor-
ders, a monospecific MRZH response was present in respec-
tively 3/37 (8%) and 3/16 (19%) while multiple responses were
never observed (15, 25, 28). In one series, 1/1 Sjögren and
1/1 Wegener and 3/9 lupus had an MRZH response (includ-
ing two with intrathecal synthesis of anti-DNA) (53). In a
series of 17 primary Sjögren’s syndrome, 11 had OCB, 6 had
a high IgG index, 13 had a high IgM index, 8 had at least a
reaction (immunoblot) against one specificity of the MRZH
pattern, but none had anti-MBP (54). Interestingly, many
series harbor a frequency of abnormal specific AI at low fre-
quency in non-MS disorders but at intermediate frequency
in the autoimmune non-MS disorders group (22, 28). When
focusing upon paraneoplastic neurological syndromes (char-
acterized by anti-Hu, -Yo, -Ri, -Ma, -Ta or -Tr antibodies either
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in serum or CSF, and by a CNS acute inflammation), a mono-
specific MRZ response was present in 7/34 vs. 0/42 in MS,
whereas a bispecific or a trispecific response was obtained in
none (0/34) of these syndromes vs. 37/42 MS patients (55). A
bispecific response was obtained in 1/20 neuromyelitisoptica
(NMO) (16). No intrathecal synthesis was observed against
CMV or EBV in a large group of amyotrophic lateral sclerosis
(ALS) and chronic inflammatory demyelinating polyneuropa-
thy (CIDP), a setting in which intrathecal synthesis is usually
absent (56). In CNS lymphoma, AI is commonly elevated for
EBV but not against measles, yet results obtained with EBV
may obscure the interpretation due to its dedicated role in
lymphoma’s pathophysiology (52).
(b) Infectious disorders. In a few cases of neuro-borreliosis,
neuro-syphilis, or neurotuberculosis, a MRZ synthesis occurs
against one species in a few percent and below 0.1% for
M+R+Z (8, 57, 58). However, neuro-syphilis should be
studied differently. There has been one case of neuro-syphilis
showing elevated AI for MRZ and mumps (59). In HIV infec-
tion, apart from elevated AI against HIV itself and HSV, C.
pneumoniae-specific OCB are found in 3/5 patients, HSV OCB
in half of all patients, as well as OCB against CMV and toxo-
plasma (25, 58, 60). In a series of 17 HTLV-1, only one showed
a complete MRZ response (57), but none did in a series of 11
HSVE (61). In another series of nine HSVE, all had a persistent
response against VZV and one had an intrathecal synthesis
against measles (62). In the latter patient, synthesis against
measles was absent at week 1, appeared at week 4, and persisted
at year 4.5 (62). In a series of seven children having suffered
from HSVE when they were younger, 3/5 who underwent lum-
bar puncture more than 8 years later had a partial or complete
MRZ pattern but none did of those who underwent lumbar
puncture in the same year (63). Moreover, IgG index increased
over time, reaching a maximum at 1–2 months, then mostly
remained elevated years later (63, 64). Systematic studies are
lacking but in a single case of HSVE,an initially high AI for her-
pes subsequently abated whereas AI against multiple viruses
(measles, parainfluenza, influenza, and adeno) increased (63).
A systematic study of 10 mumps meningitis revealed a com-
bination of multiple intrathecal reactivity against measles,
herpes, adenovirus, or rubella in most patients, in the same
range as that observed in MS patients (65). In one case,
non-specific reactivity against measles and herpes was already
present at day 1 whereas mumps reactivity appeared at day
10 (65). In acute neuro-borreliosis, the presence of an MRZ
pattern is documented in up to 7% of patients, whereas in
late neuro-borreliosis, a considerable number of OCB were
not attributable to B. burgdorferi (66), and an MRZH pattern
with three specificities was observed (58).
(c) Genetic disorders. The systematic study of CNS genetic dis-
orders may open up an unexpected window of reciprocal
intrathecal autoimmunity. A seminal work in Batten’s dis-
ease, which is a purely degenerative CNS genetic disorder,
demonstrated a high level of intrathecal antibodies against
GAD (glutamic acid decarboxylase) in patients and in the
murine model (67). Results are even more interesting in X-
linked adreno-leukodystrophy (ALD). OCB was found in only
one patient in 13 with typical ALD but was absent in asympto-
matic patients (68). However intrathecal synthesis was present
in all but 1 of the 14 ALD patients and in none of the 12
asymptomatic patients (68). This synthesis predominates in
IgA in all cases but one, but only rarely in IgG or IgM. Interest-
ingly, intrathecal synthesis was found negative in CSF sampled
before the onset of brain symptoms and later became pos-
itive. The MRZ pattern was absent in all cases, but none
had a follow-up exceeding 2 years after onset of brain symp-
toms (68). Moreover, the inflammatory component in ALD
is a secondary event, mostly localized in the center of lesions
but sparing the edges, contrary to MS (68). The two latter
examples suggest that whatever the chronic brain lesion, an
intrathecal non-specific inflammation may be triggered.
In conclusion, there is a lack of large systematic studies of
MRZH (and other specificities), AI in chronic protracted autoim-
mune brain disorders and especially in chronic brain infections,
taking into account age at infection onset, immunizations prior
to and during the infections and duration of disease. However,
the above-mentioned data strongly suggest that a polyspecific
intrathecal synthesis occurs more commonly than thought in
association with long-standing infection/post-infection intrathe-
cal specific response. In line with the progressive enrichment of
the MRZ pattern over time in MS, these observations support our
main hypothesis postulating a (slowly) progressive recruitment of
non-specific PC over time.
COULD WE USE CHRONIC NEUROLOGICAL INFECTIONS AS A MODEL
FOR THE STUDY OF NON-SPECIFIC INTRATHECAL IMMUNE
SYNTHESIS?
The above-mentioned arguments support the existence of a non-
specific intrathecal reaction associated with neurological infec-
tions. Moreover, this non-specific reaction takes years to develop,
since it is more frequent in chronic infections and in older MS
patients. The factor triggering MS and the reason why intrathe-
cal inflammation fails to clear in MS are still unknown. From a
theoretical point of view, the study of these chronic neurological
infections may open up a major opportunity that is unavailable
in MS investigations by controlling two key points: infection trig-
gers a specific (and non-specific) intrathecal inflammation and
antibiotics cure the cause. This may allow the study of the natural
clearance of CNS inflammation after the end of the cause, which
may provide information about the late progressive stages of MS.
Nevertheless, from a technical point of view, it now seems very
difficult to document non-specific intrathecal synthesis in chronic
neurological infections. Thanks to medicine and hygiene, most of
the above-mentioned chronic infections (SSPE, HTLV-1, neuro-
syphilis, chronic neuro-borreliosis) have now practically disap-
peared from westernized countries. Other chronic protracted CNS
infections such as HTLV-1, neurocysticercosis, and trypanosoma,
which are associated with a strong specific intrathecal synthesis,
are all neglected diseases from tropical areas, and medical research
into them and their treatments have been sidelined. HIV infec-
tion would lend itself to the long-term study of the progressive
enrichment of intrathecal synthesis, but immune dysfunction
might interfere during follow-up.
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FIGURE 4 | Symmetry of intrathecal synthesis paradigms in MS
and chronic CNS inflammation/infections. Intrathecal synthesis in
CNS infection implies plasma cells, and as demonstrated herein,
needs survival niches supported by TLO. Sub-pial demyelination is
associated with TLO, as classically known in MS, but also in chronic
CNS inflammation and infections. Therefore, sub-pial demyelination
induced by TLO is not a hallmark of MS and defines the concept of
TLO-pathy.
RETHINKING SUB-PIAL LESIONS OF PROGRESSIVE MS IN THE LIGHT OF
NON-SPECIFIC INTRATHECAL INFLAMMATION: INTRODUCING THE
CONCEPT OF “TLO-PATHY”
Studying intrathecal synthesis in non-MS disorders could be far
from futile. Although proof of CNS TLO is lacking in many
disorders associated with intrathecal synthesis, owing more to the
recentness of the discovery of TLO than to negative studies, no
alternative theory better explains the long-lasting intrathecal syn-
thesis observed years after neuro-infection healing, for example
after neuro-syphilis, borreliosis, or HSV (Figure 4) (62, 66, 69).
Do cortical TLO exist in chronic infections and are they associ-
ated with congruent sub-pial lesions as in progressive MS? In a
series of nine patients suffering from different types of neuro-
infections, two were proved to have meningeal B-cell aggregates
(one tuberculous meningoencephalitis, one syphilitic meningitis)
(7). Furthermore, sub-pial demyelination (layer I) was observed
in syphilitic meningitis (7). In the event of independent study
replication, sub-pial lesions associated with cortical TLO should
no longer be considered as typical of progressive MS, but should
rather be seen (at least in some cases) as bystander lesions induced
by TLO independently of the causal disorder: infection, inflam-
mations, or MS (1). Pathophysiology may involve by-products of
TLO function like cytokines (TNFα, IFNγ, etc.), which were shown
in vitro to have a noxious effect on cultured brain cells owing
to antibody-independent toxicity (45, 70, 71). As a consequence,
sub-pial lesions may be considered as typical of cortical TLO, thus
defining a“TLO-pathy,”thereby adding a major conceptual brick to
the understanding of CNS pathology. We acknowledge that these
lesions have been reported only once, but one should remem-
ber how long it took to identify these key lesions in MS and that
they were never explicitly tracked in other pathological settings.
Acknowledging also that CNS pathologies involving intrathecal
inflammation are either exceptional (like tropical infections) or
too severe to be followed up for decades, MS is nowadays by
far the most common cause of chronic intrathecal inflammation.
We suspect that this epidemiological fact has biased observation
by associating chronic intrathecal inflammation with MS, not
because the association is specific but simply because it is sta-
tistically more likely. From a theoretical point of view, it could
be important to longitudinally monitor non-MS patients with
chronic intrathecal inflammation (implying TLO presence) in
order to assess the possible development of progressive sub-pial
lesions and brain atrophy reminiscent of the MS progressive phase.
This would provide proof of TLO-pathy as a valuable new thera-
peutic target in all disorders involving intrathecal inflammation,
including the still intractable progressive phase of MS.
CAN NON-SPECIFIC INTRATHECAL SYNTHESIS SHED LIGHT
ON TIME OF MS ONSET?
INFLUENCE OF IMMUNIZATION SCHEDULE
Uncertainty remains about the timing of MS onset in the chronol-
ogy of infantile MRZ infections or vaccination in the case of
rubella, measles, and mumps. Moreover, most studies are dedi-
cated to potentially neuro-infectious agents (measles, rubella,VZV,
HSV, EBV, chlamydia), which obscure the analysis since one can-
not exclude past subtle CNS infections. What would the results be
for common infectious agents devoid of neurotropic effect (i.e.,
human papillomavirus, anti-tetanus toxin vaccine)? One might
regret that anti-tetanus toxin, which is a marker of non-specific
lymphoid IgG secretion commonly used in immunology, has never
been tested in CSF. Is the intrathecal synthesis influenced by
the schedule of immunizations (by infectious agents or vaccine)
related to the time of MS onset? In other words, is the chance
of acquiring non-specific intrathecal synthesis modified by the
time of immunization, whether it occurs before, around, or after
the clinical onset of MS? Once activated, B-cells have matured
to PC in secondary lymphoid organs in response to an antigenic
challenge, and long-lived PC migrate to bone marrow where they
definitely home in nests providing a metabolic support. In this
way, CNS may only recruit some PC during their short time frame
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of blood circulation succeeding B-cell differentiation. As a conse-
quence, it may be that more than being an immune scar from early
infection or immunization (6), non-specific intrathecal synthesis
recapitulates and freezes the major antigenic challenges endured by
the patient since MS onset. Elevated AI should be more common
in protracted chronic CNS infections than in acute infection: an
MRH reaction was described in a chronic case of neuro-borreliosis
whereas no AI was elevated (except against borrelia) in an acute
infection (58). There have been three case reports of MS with an
initially normal AI that increased on a subsequent control lum-
bar puncture: two cases corresponded to current immunization
against rubella and one case to a fresh VZV infection (72). Mon-
itoring the differential intrathecal response to vaccines received
early in life (i.e., anti-tetanus toxin) and those given later (i.e.,
hepatitis A/B, human papillomavirus) may help to demonstrate
this hypothesis.
REASSESSING THE PARADOX OF LOW INTRATHECAL ANTI-EBV
REACTION
Besides opening the debate on the significance of EBV infection
in MS (73, 74), we now focus on intrathecal reaction against
EBV (52). In a cohort of 24 CIS/MS patients selected for known
intrathecal synthesis against EBV, F s was in the same range against
EBV (median 0.65%, range 0.01–4.78%) as against MRZ (52). One
outlier patient had an F s anti-EBV of 18.2%. When considering
IgG against EBV, absolute levels are higher in most of MS patients
than controls, both in serum and in CSF (75), although high CSF
levels are more likely linked to blood-barrier dysfunction than to
intrathecal synthesis (76). However, anti-EBV intrathecal values
have shown that an unexpectedly small proportion of patients
have intrathecal synthesis (52, 56, 77–79): for example, anti-VCA
AI was elevated in 2/80 MS patients and anti-EBNA1 in 5/80, but
there was no difference with control groups (77). In a study focus-
ing on anti-EBNA1, intrathecal synthesis occurred in 5/76 MS
and in 13/75 controls (78). In CIS patients (optic neuritis) sam-
pled within 1 month after clinical onset, only 2/36 (6%) had an
elevated AI (F s 0.12–0.41%), whereas all were seropositive (52).
In another study including 43 childhood and 50 adult onset MS,
intrathecal synthesis occurred against measles, rubella, and VZV in
30–60% of pediatric and adult patients, whereas synthesis against
anti-EBNA1 and anti-VCA occurred respectively only in 21 and
14% in the pediatric group and 8 and 2% in the adult group (80).
Moreover, AI against EBV is sometimes twofold lower than AI
against each MRZ component (80) but similar elsewhere (52). A
difference in seroprevalence can be ruled out. Measles and rubella
seroprevalence resulting either from natural infection or vaccina-
tion exceed 90% in most populations and vaccination campaigns
started decades before (15), varicella seroprevalence exceeds 90%
in all European populations and EBV seroprevalence is virtually
complete in MS patients.
The lower than expected intrathecal response against EBV is not
consistent with the strong correlation linking high serum anti-EBV
levels and MS activity. In the light of this finding, such an extreme
discrepancy can be interpreted as a strong clue for EBV infection
preceding MS clinical onset (52). Similarly, one can suppose that
EBV infection triggers a strong humoral response during which
the homing of EBV-specific long-lived PC mostly precedes the
onset of intrathecal inflammation and the formation of brain TLO.
As a consequence, EBV-specific PC have less likelihood of being
recruited by brain TLO, and therefore intrathecal AI against EBV
remains paradoxically low. A different interpretation may involve
a driving role of EBV-infected B-cells and PC (81), potentially
modifying their ability to secrete antibodies against EBV antigens.
The peculiar relation of EBV with MS pathology is reinforced by
the demonstration of a high intrathecal EBV-specific CD8+ cyto-
toxic activity only early in MS patients, without recruitment of
CD8+ cells against different targets (CMV-specific CD8+ cells)
(82). Longitudinal studies of patients’ CSF for MRZ and EBV may
help to assess whether the paradox of the low anti-EBV reaction
is attributable to the schedule of primary infection or to a key
pathophysiological point.
DERIVING PRACTICAL CONSEQUENCES FOR MS CARE. CAN
WE INFER CNS TLO FROM A SIMPLE CSF ANALYSIS?
A growing set of evidence points to a central role of TLO in the
formation and maintenance of intrathecal synthesis. Moreover,
cortical TLO may play a key role in progressive MS (1, 42, 83, 84).
Yet even though TLO structures may reach a considerable diam-
eter (up to 1.1 mm), which may make them a target for future
neuroimaging, most of them are barely detectable (about 50–100
cells) even after a thorough pathological examination (85). Unless
uncovering a specific marker, TLO confirmation by conventional
MRI seems a flimsy hope and biological techniques may be more
advisable. Is there a CSF biological marker of TLO presence or
persistence?
Tertiary lymphoid organs are able to support local clonal prolif-
eration of B- and T-cells and provide survival niches for PC. T-cell
clonal response has been demonstrated to be both “private” to
brain regions and“public”since it is shared throughout the brain in
all MS patients, and TCR clonotypes are strictly private to patients
(46). Clonotype analysis of B-cell repertoire in multiple anatomi-
cal brain areas, including meningeal aggregates and CSF, showed a
large overlap between local repertoires. As a consequence, analysis
of the CSF clonotype repertoire gives a representative sample of
the meningeal repertoire (86, 87). The CSF B-cell family germline
repertoire is strongly biased to VH4 and VH3 (88) and private
clonotypes are expanded from single ancestors (89, 90). Somatic
hypermutations in CDR within RGYW/WRCY motifs of IgG (47),
which are targeted by the activation-induced cytidinedeaminase
(AICD) specifically expressed in lymphoid organs, suggest that
most of these lineage cells have undergone a local germinal cen-
ter reaction (91). All these indirect arguments strongly suggest
the presence of TLO but necessitate high-level biological tests
unavailable in routine practice. In fact, intrathecally produced
IgG – elevated index, specific F s, OCB – is one of the major ter-
minal products of TLO production and seems to be a valuable
indirect hallmark of CNS TLO. To date, no therapy has reversed
acquired intrathecal synthesis in MS. A series of 76 patients treated
by natalizumab offers one exception: 16% were controlled nega-
tive for OCB after treatment, and the proportion of patients with
an intrathecal synthesized fraction in the normal range increased
from 20 to 45% (44). As a consequence, we propose that intrathe-
cal IgG secretion could be used to monitor future TLO-targeted
therapies.
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We therefore hypothesize that intrathecal immune suppression
should negate intrathecal IgG secretion by clearing CNS TLO (1).
Clinical trials using intrathecal drugs offer a real hope to cure pro-
gressive MS. However, these trials were designed to use intrathecal
rituximab. A pitfall of this treatment may be the resistance of
CD20+ B-cells nested in TLO as observed in rheumatoid arthritis,
and the persistence of local IgG secretion as observed in serum (1,
92). In fact, after intravenous+ intrathecal rituximab treatment,
a complete B-cell depletion is obtained in serum but depletion is
still incomplete in CSF at 3 months: −85% for B-cells,−82% for
T-cell (93). Results for IgG secretion and clinical/radiological data
are not yet available. Although incomplete, these results suggest
that intrathecal rituximab is a first step, but that it may not be
sufficient alone to eradicate CNS TLO.
CONCLUSION
Although typical of MS, the non-specific intrathecal reaction has
long been a theoretical issue. We propose to consider this non-
specific reaction as a common physiological property of intrathe-
cal inflammation, involving the general properties of TLO located
in the CNS. We extend this concept to (non-MS) CNS autoim-
mune and infectious disorders associated with intrathecal synthe-
sis. Moreover, we propose that the cortical lesions associated with
TLO observed in MS are not specific for MS but for TLO. We
therefore propose the concept of “TLO-pathy” to describe cortical
lesions associated with the presence of TLO. The concept of non-
specific secretion deserves further study to clarify the influence of
immunization schedule.
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